Novo Nordisk (NYSE: NVO), the Danish drugmaker of GLP-1 weight loss drugs Ozempic and Wegovy, slipped 2% through 10:30 a.m. ET Friday after suffering a one-two punch from Reuters and a bank analyst.

Reuters warns that Novo Nordisk's growth rate is slowing. Singapore bank DBS says the stock is a sell. But at 18 times earnings and with a growth rate of 16% or better, Novo Nordisk actually looks ...

The U.S. Food and Drug Administration (FDA) and drug manufacturer Novo Nordisk are warning consumers about “counterfeit” Ozempic found outside the authorized drug supply chain. The contents of ...

Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has been struggling during the past year. Its financial results -- though strong by comparison to most of its peers -- haven't been as ...

LONDON, April 24 (Reuters) - Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk (NOVOb.CO), opens new tab has raised its annual sales guidance several times a year.

Novo Nordisk's sales have been growing fast thanks to GLP-1 medicines like Ozempic for diabetes and Wegovy for weight management. In 2024, revenue increased by 25% year over year to 290 billion ...

Novo Nordisk's shares fell on news of a clinical success from its biggest rival. As a result, it could lose market share in an important area. However, there are still strong reasons to invest in ...

Novo Nordisk has filed 111 lawsuits in 32 states to stop the sale of dangerous, mislabeled, or impurity-laden knockoff semaglutide drugs. Don't face extreme market conditions unprepared.

Denmark-based global pharma major, Novo Nordisk is now phasing out its Human Mixtard penfill by the year end. However Mixtard in India will continue to be available in vials. Along with it, other form ...